In Brief: U.S. Surgical Abbi
This article was originally published in The Gray Sheet
U.S. Surgical Abbi: USSC will provide clinical data to FDA on its Abbi minimally invasive breast biopsy system in an ongoing effort to convince the agency to allow marketing of the device under its current 510(k). U.S. Surgical says it expects a "positive" outcome to the discussions and notes that it can continue selling the device pending resolution of the issue. The firm announced June 4 that FDA had indicated it may have made an error in issuing the 510(k) and was considering rescinding the premarket notification clearance ("The Gray Sheet" June 10, I&W-10). USSC also is holding discussions with the agency to resolve outstanding labeling and advertising issues regarding the Abbi system raised in a June 3 warning letter to the company...
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.